Tonix Pharmaceuticals Holding Co (TNXP) 宣布，预计将于今年年中启动其候选药物Tonmya用于治疗重度抑郁症（MDD）的二期临床研究。
这一进展标志着该公司在拓展其核心产品管线方面迈出了重要一步。重度抑郁症是一种常见且严重的精神健康障碍，对全球数百万人产生影响，目前仍存在大量未满足的临床需求。
Tonmya作为一种新型潜在疗法，其二期研究旨在评估该药物对MDD患者的疗效与安全性。公司计划在年中启动这项研究，具体时间表将取决于监管机构的反馈和最终的准备工作。
此次研究启动的预期，反映了Tonix Pharmaceuticals在推进其神经精神疾病治疗产品开发方面的持续努力。市场将密切关注该研究的后续进展及其可能带来的临床价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.